Tag: cannabis

  • Canopy Growth, Martha Stewart Launch New CBD Line

    Canopy Growth, Martha Stewart Launch New CBD Line

    Credit: CNW Group/Canopy Growth Corporation

    Martha Stewart CBD has launched a line of need-based CBD gummies.

    The new line was developed in response to consumer demand for targeted solutions that address their most common needs: sleep, stress, and the discomfort of aches and soreness, according to press release.

    Each product is formulated with higher levels of CBD and powerful co-active ingredients selected for their known efficacy.

    “I’m often asked how I maintain my energy with such a busy schedule, and for me it’s essential to start each day well-rested, unbothered, and pain-free,” said Stewart, a chef, television personality and entrepreneur. . “I discovered CBD several years ago as a simple, effective, and natural solution to help address the discomforts of everyday life. Having benefited greatly from it myself, I set out to create a delicious and premium line of gummies that taste as good as they make you feel.”

    In partnership with Marquee Brands and Canopy Growth Corporation, Stewart’s new solution-oriented formulations combine “her signature elevated flavor profiles with Canopy Growth’s unique consumer insights” and industry innovation. The new offerings include:

    • Sleep CBD Gummies: A berry medley with notes of Montmorency cherry, elderberry, and boysenberry;
    • Chill CBD Gummies: A citrus-forward concoction of tangerine, yuzu, and pomelo;
    • Extra Strength CBD Gummies: An orchard-inspired blend of pluot, apricot, and California red peaches.

    “As consumers focus on finding the ways to feel their best, CBD use continues to grow, fueled by categories like gummies that have become an integral part of wellness routines,” said Tara Rozalowsky, chief growth officer and president for Canopy Growth, according to a press release. “Martha Stewart is a trusted household name because people of all ages turn to her for candid advice and simple, sensible solutions to everyday problems. The new Martha Stewart CBD needs-based gummies deliver just that – accessible, reliable relief when and where you need it most.”

  • Blinc Group Taps Sahani to Replace CEO Dumas de Rauly

    Blinc Group Taps Sahani to Replace CEO Dumas de Rauly

    Arnaud Dumas de Rauly
    Arnaud Dumas de Rauly / Credit: The Blinc Group

    The Blinc Group, a cannabis vaporizer industry innovator, announced that Pete Sahani, who has been serving as the company’s COO since 2022, has been named CEO. Sahani is replacing vaping industry legend Arnaud Dumas de Rauly, co-founder and current CEO.

    Dumas de Rauly will be stepping down from that role to embark on a new strategic direction within the company as chief experience and science officer (CXSO) and will retain his position on the Blic Group board. This transition will become effective as of Dec. 1, 2023.

    Dumas de Rauly has been at the helm of The Blinc Group since 2018, guiding the company through substantial growth phases and establishing it as a key player in the cannabis vaping space, according to a press release.

    Pete Sahani

    “Arnaud has been a visionary leader, under whose guidance Blinc has established itself as a major player in the cannabis vaping space, and has always done so while keeping a strong focus on consumer safety,” said co-founder and chief innovations officer Sasha Aksenov. “His strategic foresight has been invaluable, and we are certain that he will continue to play a pivotal role in Blinc’s future.”

    As CXSO, Dumas de Rauly will drive Blinc’s growth through strategic partnerships and innovation. He will focus on integrating analytical science and consumer safety with superior customer experiences, ensuring Blinc paves the way in both technology and user satisfaction.

    Sahani brings a wealth of experience to his new role as CEO, having been instrumental in a number of key initiatives at Blinc since joining the company as COO in April 2022.

    “Pete has been a pivotal figure in our leadership team, playing a significant role in not only steering us to positive EBITDA and Net Income but also in the introduction of innovative services like Scale Now Pay Later (SNPL) and Vendor Managed Inventory (VMI),” commented Arnaud Dumas de Rauly. “With his exceptional skill in operational management and strategic planning, I am confident that Pete is the ideal leader to propel Blinc into a future marked by sustained profitability and expanded service offerings.”

    Pete Sahani expressed his enthusiasm about the new role, “It’s an honor to step into the CEO role at The Blinc Group. I am excited to build upon the strong foundation laid by Arnaud and our team by leading the company towards new heights of innovation and market leadership.”

    The leadership transition is part of The Blinc Group’s ongoing strategy to adapt and thrive in the dynamic cannabis industry. The company remains committed to its mission of delivering high-quality, innovative vaporizer solutions and complimentary services while expanding its global footprint.

  • Chill Brands to Sell CBD Vapes in WH Smith Stores

    Chill Brands to Sell CBD Vapes in WH Smith Stores

    Credit: William

    Chill Brands said it will sell its nicotine-free CBD vapor products in U.K.-based WH Smith stores.

    The cannabidiol-products company on Monday said a range will be for sale in an initial 150 of WH Smith’s 1,700 stores, according to a press release.

    “These first outlets are WH Smith U.K. travel stores located in airports, train stations and other high-traffic hubs including Heathrow, Gatwick and Kings Cross Station. These areas benefit from an estimated combined daily footfall of more than 500,000 passengers per day,” it said.

    Further to the agreement, it has now secured initial orders worth more than 350,000 Pounds ($428,365) from U.K. retailers, it added.

    Chill Brands said that it continues to work to expand its retail distribution network in the U.K. and the U.S.

  • Legal Insight

    Legal Insight

    Credit: Federico Magonio

    By Jean Gonnell, Christina Sava and Nicholas Ramos (Troutman Pepper Hamilton Sanders Tobacco and Cannabis Team)

    Across the United States hemp products seem to be everywhere. From corner stores to spas, one can find a hemp- or CBD-infused version of almost anything. Hemp and its derivatives are found in foods, cosmetics, hand-rolled cigarettes and vape pens. A new category of “intoxicating hemp products,” such as delta-8 THC products, have taken the hemp industry by storm. Although the market is vast, the regulatory landscape contains many pitfalls. Potential market entrants must carefully research the applicable laws, and take into account any federal-level risks, before deciding to invest in a hemp or hemp-derived products venture. This article reviews the legal status of hemp-derived products, including smokable hemp products, at the state and federal levels.

    Marijuana and Hemp

    Marijuana and hemp come from the same plant: Cannabis sativa L., or “cannabis” for short. Cannabis has a long history of industrial and medicinal uses, and only a short history of prohibition, which we now see unraveling. “Hemp” is the common term for cannabis with a concentration of delta-9 tetrahydrocannabinol (“THC”) of .3% and under, while “marijuana” is used to mean cannabis with a delta-9 THC concentration over .3%.  Marijuana remains a Schedule I substance under the Controlled Substances Act (“CSA”). Hemp production, on the other hand, was legalized by the Agricultural Improvement Act of 2018, or 2018 Farm Bill. At that time, Congress removed “hemp” and “tetrahydrocannabinols in hemp” from the CSA’s definition of “marijuana.” Specifically, the 2018 Farm Bill defined “hemp” as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis.” 7 U.S.C. § 1639o.

    So, although they are technically the same plant, hemp and marijuana fall under completely different regulatory regimes, with a single cannabinoid – delta-9 THC – determining whether a cannabis plant or product is hemp or marijuana.

    THC, CBD, and Other Cannabinoids

    There are over 100 cannabinoids found in cannabis. Perhaps the most well-known of these are cannabidiol, or CBD, and delta-9 THC. CBD is considered non-psychoactive and generally prized for its therapeutic potential. Delta-9 THC has long been recognized as the cannabinoid that causes users to feel “high.” Since the 2018 Farm Bill, however, other psychoactive THCs, such as delta-8 and delta-10 THC, have been identified in cannabis. The “high” produced by delta-8 THC has been described as partway between THC and CBD, with relaxing body effects and a less-potent “head-high,” while delta-10 has been described as producing a more cerebral high akin to sativa strains of marijuana.

    So why the boom in delta-8 and delta-10 THC products now? They can be derived from hemp. Although found in much lower quantities in hemp than other cannabinoids, manufacturers have found ways to chemically convert hemp-derived CBD into delta-8 and delta-10 THC. Even delta-9 THC is being converted from CBD, and manufacturers are adjusting product ratios to remain within the .3% limit. The Cannabis Regulators Association has called this the “0.3% loophole” and stated: “While the threshold of 0.3% delta-9 THC (tetrahydrocannabinol) by weight is a small amount of THC in a hemp plant, when applied to hemp-derived products (e.g., chocolate bars, beverages, etc.) which can weigh significantly more, 0.3% by weight can amount to hundreds of milligrams of THC. For example, a 50-gram chocolate bar at 0.3% THC would have around 150 mg of THC (30 times the standard 5 mg THC dose established by the National Institute on Drug Abuse).”[1]

    The Drug Enforcement Administration (DEA) more or less gave the hemp-derived delta-8 industry a green light in a September 2021 letter to the Alabama Board of Pharmacy. The Board of Pharmacy inquired as to the control status of delta-8 THC under the CSA. DEA concluded that “cannabinoids extracted from the cannabis plant that have a [delta-9]-THC concentration of not more than 0.3 percent meet the definition of ‘hemp’ and thus are not controlled under the CSA.” Thus, so long as delta-8, delta-10, and other extracts are derived from a cannabis plant with less than 0.3% delta-9 THC, they constitute “hemp,” which is federally legal.

    Notably, “synthetic tetrahydrocannabinols” remain a schedule I substance under the CSA. Some argue that because delta-8 and delta-10 are produced through a form of synthesis, they are Schedule I “synthetic tetrahydrocannabinols.” Regardless of this argument’s merit, this is not the position DEA has taken thus far, and we do not see any indication that they will suddenly take this position in the near future.

    FDA Enforcement and the Future of CBD Regulation

    Nonetheless, hemp-derived CBD and THC products are still not legal to be sold as a drug, dietary supplement, or food, according to the Food and Drug Administration (FDA). To the extent a manufacturer markets its delta-8 (or CBD) products as intended to affect the structure or any function of a consumer’s body, FDA’s position is that the product is an unapproved drug. In addition, “food” (almost anything edible that is not an approved drug or lawful dietary supplement) may not contain unapproved additives. Any form of CBD and THC are not approved food additives.

    FDA has also concluded that THC and CBD products cannot be marketed as dietary supplements, because the definition of “dietary supplement” excludes active ingredients that have been approved as drugs or have been authorized for investigation as a new drug. THC and CBD are both active ingredients in at least one FDA-approved drug. Other parts of the hemp plant that do not contain THC or CBD might be available for use as dietary supplements, so long as manufacturers abide by related requirements, including notifying FDA.

    And, FDA is watching the marketplace closely and taking enforcement action where it sees fit. FDA has issued numerous warning letters to companies selling hemp-derived CBD and THC products with impermissible health or therapeutic claims; for misbranding, such as lacking adequate directions for use; and for using these cannabinoids as an unapproved additive in foods, such as gummies, chocolate, caramels, chewing gum, and peanut brittle. The agency has also published a general health warning for delta-8 products.

    Industry and regulators alike have been anticipating some kind of regulatory action by FDA, but it appears this is yet far off. In January of this year, FDA determined that it does not have the appropriate regulatory pathway to regulate CBD products and called on Congress to pass legislation creating a new pathway separate from the food, drug, or dietary supplement pathway. Despite this regulatory uncertainty, sales of CBD products in the U.S. continue and could reach as high as $20 billion by 2025.

    States and Hemp-Derived Products

    Given the lack of federal standards and delta-8 and delta-10 (and likely other THCs’) psychoactive effects, state lawmakers are taking action to regulate products containing these extracts. At least 22 states have restricted or banned the sale of delta-8 THC products, while others are in the process of reviewing the cannabinoid’s status. One common way states are doing this is by limiting the total concentration of THC a product can have, rather than mirroring federal law and limiting only delta-9 THC concentrations. In Colorado, lawmakers have passed SB23-271, which goes further and actually classifies nonintoxicating cannabinoids, potentially intoxicating cannabinoids, and intoxicating cannabinoids. Products will be regulated according to which category of cannabinoids they contain.

     In many states, a “ban” actually means that these products will only be available in licensed cannabis dispensaries where regulators can more easily track their production and sale, ensure that the products pass required contaminant testing, and prevent the products from being sold to minors. Retailers and manufacturers of hemp derived products, especially those wanting to sell nation-wide, must be diligent in tracking state by state restrictions on hemp-derived products.

    Smokable Hemp

    Smokable hemp, although it receives less attention than other forms of hemp products, is a major driver of hemp product sales. Smokable hemp is hemp flowers after they have been manicured and dried. Smokable hemp can be sold as “buds” or in pre-rolled hemp cigarettes. This hemp looks and smells a lot like traditional marijuana but is not psychoactive. While some users may feel a mild mellowing effect, most do not feel “high” after smoking hemp. This may be why smokable hemp is the only hemp product category that has experienced wholesale price increases over time.

    The legal status of smokable hemp, however, also varies from state to state. Smokable hemp is illegal for sale in a handful of states, including Idaho, Iowa, Kentucky and Massachusetts. Other states do not place any restriction on its sales.

    New York has banned hemp flower products that are “clearly labeled or advertised for the purpose of smoking or in the form of a cigarette, cigar or pre-roll.” California does not currently permit the sale of any “inhalable hemp” products, however labeled, having passed a law that prohibits the sale of such products until a tax on the products has been enacted. No such tax is yet in effect.

    ***

    Given the above, it is not safe to assume that your hemp product is legal for sale because hemp is federally legally. It is important for retailers and manufacturers to be aware of the laws that apply to the types of hemp products they are selling. Although the DEA has been hands-off since the passage of the 2018 Farm Bill, FDA oversees all foods, drugs, and dietary supplements in the U.S. and maintains that THC and CBD, even though hemp derived, may not be added to foods and dietary supplements, or marketed as drugs. FDA does not oversee inhalable substances generally, and thus has not released statements related to the legality of smokable hemp. Smokable hemp may be a good market entry point, especially for manufacturers and retailers already familiar with highly-regulated inhalable products.  

    Troutman Pepper’s Cannabis Practice provides advice on issues related to applicable state law. Cannabis remains an illegal controlled substance under federal law. Its attorneys are available to provide more information about these opportunities.


    [1] See https://www.cann-ra.org/news-events/sx2s63c2fudq9n0zmk4ekviku9747f.

  • Bill Morachnick to Serve as CEO at Charlotte’s Web

    Bill Morachnick to Serve as CEO at Charlotte’s Web

    Image: Tobacco Reporter archive

    Charlotte’s Web Holdings appointed William (Bill) Morachnick as CEO. Morachnick has also been appointed to the company’s board of directors as a nonindependent director. He replaces CEO Jacques Tortoroli, who has elected to resign from his roles at Charlotte’s Web.

    Morachnick has a record of building premium, differentiated products and brands across multiple channels throughout the world and across a broad range of product categories.

    Prior to joining Charlotte’s Web, Morachnick was president at Santa Fe Reynolds Tobacco International Zurich (SFRTI) from 2006 to 2016. He took SFRTI from a startup to a highly profitable organization, managing several hundred employees and a network of importers/distributors operating in Europe, Asia and the Middle East. SFRTI was acquired by Japan Tobacco Group in 2016 for $5 billion. Morachnick led the subsequent integration of the combined companies as CEO and chairman based in Tokyo, Japan, for two years before returning to the U.S. in 2018.

    Since returning to the U.S., he has served as an executive advisor or board member for several companies seeking to launch and/or expand their businesses in the U.S. and overseas markets.

    “Bill has an accomplished career building businesses in multiple categories,” said John Held, chairman of Charlotte’s Web. “With his proven operational expertise, Bill is well suited to take the reins to lead the Charlotte’s Web team through the next phase of the company’s growth opportunities.”

    The company expressed its gratitude to Tortoroli for his contributions. ‎“Jacques served on the company’s board since November of 2019 and as CEO since late 2021 in a difficult environment devoid of regulatory oversight and clarity,” said Held. “Under his leadership as CEO, Jacques streamlined the organization, reduced the cash burn and recapitalized the company through a strategic $57 million investment from BAT via a convertible loan.”

    In November 2022, BAT announced a £48.2 million ($57.4 million) investment in Charlotte’s Web.

  • McKinney Regulatory Science Reveals New Website

    McKinney Regulatory Science Reveals New Website

    McKinney Regulatory Science Advisors has launch its new website that promises “a new era of innovation and transparency for their clients,” according to a press release.

    The new platform describes an array of advisory services to nicotine and cannabis clients, with an emphasis on providing McKinney clients with the best available regulatory services.

    Willie McKinney, CEO of McKinney, said the new website represents a significant milestone in journey to provide exceptional advisory services to our nicotine and cannabis clients.

    “The revamped platform reflects our dedication to innovation, transparency, and client satisfaction, making it easier for clients to explore our services and access valuable regulatory resources,” he said

    The new website offers a modern design that makes it easy for users to find the information they need quickly. It also features an intuitive navigation system that allows users to identify relevant services and access helpful resources rapidly, according to McKinney. Additionally, the site is optimized for mobile devices so that users can access the site from any device at any time.

    “McKinney RSA focuses on providing comprehensive solutions that meet complex regulatory requirements while also delivering superior customer service,” the release states. “With decades of industry experience under their belt, they are committed to helping their clients succeed by providing top-notch guidance every step of the way.”

  • U.S. Congress Committee to Discuss CBD Thursday

    U.S. Congress Committee to Discuss CBD Thursday

    A U.S. congressional committee is scheduled to talk about hemp this week as lawmakers presumably will increase pressure on the U.S. Food and Drug Administration to establish guidelines to regulate the CBD market.

    A hearing set for 2 p.m. Thursday will look at “Hemp in the Modern World: The Yearslong Wait for FDA Action.”

    The House Oversight and Accountability Subcommittee on Health Care and Financial Services session is open to the public and also may be viewed online, according to Hemp Today.

    The session is also likely to address what some say is a lack of regulatory clarity and concern about the safety of synthetic delta-8 THC products.

    The oversight committee, chaired by Rep. James Comer, is investigating the FDA’s failure to regulate hemp-derived CBD products as dietary supplements.

    Lawmakers and the FDA have danced around CBD for nearly five years, with Congress repeatedly calling on the agency to set rules for the unregulated products, which emerged beginning late last decade and grew into a flourishing gray market.

    “We are going to investigate why exactly the FDA has decided to ignore their regulation responsibilities related to CBD and other areas of jurisdiction,” said Rep. Lisa McClain, who serves on the committee.

    “Without these regulations, dangerous products could make their way to the shelves while safe and credible CBD products could be prevented from entering the market,” McClain said.

  • Michigan Recalls THC Vapes for Banned Chemical

    Michigan Recalls THC Vapes for Banned Chemical

    The Cannabis Regulatory Agency in Michigan is recalling certain THC vape cartridges due to the possible presence of banned chemical residue exceeding the established limits, the agency announced.

    The vape cartridges — manufactured under the name “FLIGHT LIVE RESIN DISPOSABLE” — were manufactured by the Mount Morris-based marijuana processor Sky Labs near Flint and include three batches called “Grease Monkey,” “Space Ether” and “Bubblegum,” according to the Detroit Free Press.

    More than 13,000 of these vape cartridges have been sold, David Harns, a spokesperson for the CRA said, and about 2,200 of them are currently available for sale at 59 dispensaries.

    The banned chemical residues that are possibly in the products include Bifenthrin (an insecticide), Myclobutanil (a chemical used as a fungicide), Bifenazate (a pesticide), Paclobutrazol (an organic compound used as a plant growth retardant and fungicide) and Permethrin (an insecticide), he said.

  • Lawmakers File Bills To Address FDA CBD Regulation

    Lawmakers File Bills To Address FDA CBD Regulation

    Courtesy: US FDA

    Four U.S. senators separately filed legislation on Thursday that would remove regulatory barriers that the U.S. Food and Drug Administration claims prevent it from allowing CBD sales in the food supply or as dietary supplements.

    The Hemp Access and Consumer Safety Act, which was also introduced last Congress but did not advance, would exempt “hemp, hemp-derived cannabidiol, or a substance containing any other ingredient derived from hemp” from certain federal restrictions while permitting officials to enact labeling and packaging rules, according to media reports.

    Now lawmakers are gearing up to address FDA’s inaction at the subcommittee hearing formally.

    A congressional committee has scheduled a hearing for next week focused on the FDA’s refusal to enact regulations to allow for the marketing of hemp-derived CBD products. And bipartisan and bicameral lawmakers have separately reintroduced a bill to fill the regulatory gap.

    The House Oversight and Accountability Subcommittee on Health Care and Financial Services scheduled the hearing—titled “Hemp in the Modern World: The Years long Wait for FDA Action”—for July 27.

    Rep. James Comer, who chairs the full committee, has sharply criticized FDA after the agency announced in January that it would not be developing CBD regulations, stating that there is not an available pathway to create such rules and it would require congressional action.

    Meanwhile, Comer said in April that his panel would be launching an investigation into the matter, and he requested that the FDA turn over documents related to its decision not to regulate the cannabinoid. Even before the agency made that decision, the congressman expressed his intent to address the lack of rules.

    Jonathan Miller, general counsel to the U.S. Hemp Roundtable, will be among those testifying at the meeting, the organization announced in a press release on Thursday.

  • Pure Spectrum Signs CBD Deal With Kansas City Royals

    Pure Spectrum Signs CBD Deal With Kansas City Royals

    Vapor Voice Archives

    A new partnership with a cannabis brand to promote education about the potential therapeutic benefits of CBD has been formed by the Kansas City Royals—the second Major League Baseball (MLB) team to do so.

    The Missouri-based team announced last week that it has joined forces with Pure Spectrum CBD, a company that produces hemp-derived cannabidiol products like oils and gummies, according to Marijuana Moments.

    This is the second MLB team to embrace the cannabis space, coming just two months after the Chicago Cubs teamed up with the CBD sparkling beverage brand MYND DRINKS.

    MLB itself announced its league-wide partnership with a popular CBD brand last year. Charlotte’s Web Holdings, one of the most recognizable hemp-derived CBD companies, signed the deal with the league to become the “Official CBD of MLB.”

    “The Kansas City Royals are proud to be just the second MLB team to form a partnership with a company like Pure Spectrum,” Sarah Tourville, the team’s executive vice president and chief commercial & community impact officer, said in a press release. “For this organization, this opportunity gives us a chance to support a brand with Kansas City ties and to educate the community on the benefits of CBD.”